Archive for April, 2010

Approximately one year ago, the U.S. Food and Drug Administration (FDA) approved a unique IR formulation of generic omeprazole (Zegerid) to treat a variety of acid-related disorders and to reduce the risk of upper gastrointestinal bleeding in critically ill patients (Table 1). This compound was developed by combining a highly effective PPI (omeprazole) with an [...]

Like the delayed-release, enteric-coated, oral PPI formulations, IR-OME may prolong the elimination of drugs that are metabolized by oxidation in the liver, such as diazepam (Valium, Roche), warfarin generic (Coumadin candian, Bristol-Myers Squibb), and generic phenytoin (Dilantin drug, Pfizer). Increased International Normalized Ratios (INRs) and prothrombin times have been reported in patients receiving concomitant warfarin [...]

PROTON PUMP INHIBITORS: AN OVERVIEW
Acid-related disorders encompass a wide variety of diagnoses, including the extremely prevalent gastroesophageal reflux disease (GERD), which affects an estimated 25 million Americans, duodenal and gastric ulceration, stress-related mucosal disease, and acute upper gastrointestinal bleeding, a common medical emergency resulting in approximately 300,000 hospitalizations annu-ally. During the last three decades, the management [...]

Speaker: Dimitrios P. Kontoyiannis, MD, ScD, Professor, Section of Infectious Diseases, Department of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Posaconazole (Noxafil, Schering-Plough), a novel, extended-spectrum triazole antifungal agent, may offer an attractive oral treatment alternative for patients with zygomycosis who cannot tolerate or do not respond to IV amphotericin B formulations [...]

Speaker: Henry S. Sacks, MD, PhD, Professor of Community Medicine, Medicine, and Biomathematics, Mount Sinai School of Medicine, New York, New York
In hospitalized patients who are starting antibiotic therapy, the simultaneous administration of probiotics such as live, nonpathogenic microorganisms (e.g., Lactobacillus or Sac-charomyces) may prevent antibiotic-associated diarrhea (AAD) and reduce costs, and it probably saves [...]

Speaker: Michael Corrado, MD, Physician of Infectious Diseases and President and Chief Executive Officer, Advanced Biologics, New Hope, Pennsylvania
Faropenem medoxomil (Orapem, Replidyne, Inc.), an investigative oral penem antibiotic with potent activity against Staphylococcus aureus and Streptococcus pyogenes, proved to be at least as effective as generic amoxicillin/clavulanate (Augmentin canadian, GlaxoSmithKline) in the treatment of uncomplicated [...]

Telithromycin Preferred for Acute Maxillary Sinusitis
Speaker: Itzhak Brook, MD, MSc, Professor, Department of Pediatrics, Georgetown University School of Medicine, Washington, DC
The ketolide telithromycin (Ketek, Sanofi Aventis) has been found to be more effective than the macrolide azithromycin (Zithromax generic, Pfizer) in eradicating Streptococcus pneumoniae from the nasopharynges of patients with acute maxillary sinusitis. Furthermore, the [...]

Pages: Prev 1 2 3 4 Next

About this blog

Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.

Photostream

    IMG_3265
    Split Rock
    Woman at work--physician
    Ibuprofen to the Rescue [33/366]
    Elms and Biodiversity
    Placebo
    Elderberry Syrup
    condurango
    maltoleum
  • Shelby Miller: Hi, i'm doing a project called History day. The theme is innovation in history and I choose Anesthes [...]
  • Tim Tav: For newly qualified dentists it may help to join firms with a training department that may help to s [...]
  • Prierien: Great. Now I can say thank you! [...]
  • Mark: I bookmarked this link. Thank you for good job! [...]
  • Robor: Hi, Thank you! I would now go on this blog every day! Robor [...]

Tags